Navigation Links
Pharmaceuticals: Global Industry Guide
Date:3/19/2012

NEW YORK, March 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceuticals: Global Industry Guide

http://www.reportlinker.com/p0191852/Pharmaceuticals-Global-Industry-Guide.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceu

Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.

Scope of the Report

* Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Covers the Global, European and Asia-Pacific markets as well as individual chapters on 5 major markets (France, Germany, Japan, the UK and the US).

* Includes a five-year forecast of the industry

Highlights

The global pharmaceuticals market grew by 3.6% in 2010 to reach a value of $733,104.8 million.

In 2015, the global pharmaceuticals market is forecast to have a value of $981,050.8 million, an increase of 33.8% since 2010.

Americas accounts for 44.6% of the global pharmaceuticals market value.

Pfizer is the leading player in the global pharmaceuticals market, generating a 9.4% share of the market's value.

The pharmaceutical market is characterized by strong buyer power, with the ease of market entry strongly affected by legal and regulatory frameworks

The global pharmaceuticals market grew by 3.6% in 2010 to reach a value of $733,104.8 million.

In 2015, the global pharmaceuticals market is forecast to have a value of $981,050.8 million, an increase of 33.8% since 2010.

Americas accounts for 44.6% of the global pharmaceuticals market value.

Pfizer is the leading player in the global pharmaceuticals market, generating a 9.4% share of the market's value.

The pharmaceutical market is characterized by strong buyer power, with the ease of market entry strongly affected by legal and regulatory frameworks

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The pharmaceuticals market consists of ethical drugs for in-patient and out-patient usage, valued at ex-manufacturer prices. All exchange rates have been calculated using 2010 annual average exchange rates.

TABLE OF CONTENTSEXECUTIVE SUMMARY 2INTRODUCTION 19What is this report about? 19Who is the target reader? 19Market definition 19GLOBAL PHARMACEUTICALS 20Market overview 20Market value 21Market segmentation 22Market share 23Five forces analysis 24Market forecasts 36PHARMACEUTICALS IN ASIAPACIFIC 37Market overview 37Market value 38Market segmentation 39Market share 40Five forces analysis 41Market forecasts 52PHARMACEUTICALS IN EUROPE 53Market overview 53Market value 54Market segmentation 55Market share 56Five forces analysis 57Market forecasts 69PHARMACEUTICALS IN BELGIUM 70Market overview 70Market value 71Market segmentation 72Market share 73Five forces analysis 74Market forecasts 85Macroeconomic indicators 86PHARMACEUTICALS IN CANADA 88Market overview 88Market value 89Market segmentation 90Market share 91Five forces analysis 92Market forecasts 103Macroeconomic indicators 104PHARMACEUTICALS IN CHINA 106Market overview 106Market value 107Market segmentation 108Market share 109Five forces analysis 110Market forecasts 121Macroeconomic indicators 122PHARMACEUTICALS IN FRANCE 124Market overview 124Market value 125Market segmentation 126Market share 127Five forces analysis 128Market forecasts 139Macroeconomic indicators 140PHARMACEUTICALS IN GERMANY 142Market overview 142Market value 143Market segmentation 144Market share 145Five forces analysis 146Market forecasts 157Macroeconomic indicators 158PHARMACEUTICALS IN ITALY 160Market overview 160Market value 161Market segmentation 162Market share 163Five forces analysis 164Market forecasts 175Macroeconomic indicators 176PHARMACEUTICALS IN JAPAN 178Market overview 178Market value 179Market segmentation 180Market share 181Five forces analysis 182Market forecasts 193Macroeconomic indicators 194PHARMACEUTICALS IN THE NETHERLANDS 196Market overview 196Market value 197Market segmentation 198Market share 199Five forces analysis 200Market forecasts 212Macroeconomic indicators 213PHARMACEUTICALS IN SPAIN 215Market overview 215Market value 216Market segmentation 217Market share 218Five forces analysis 219Market forecasts 230Macroeconomic indicators 231PHARMACEUTICALS IN THE UNITED KINGDOM 233Market overview 233Market value 234Market segmentation 235Market share 236Five forces analysis 237Market forecasts 248Macroeconomic indicators 249PHARMACEUTICALS IN THE UNITED STATES 251Market overview 251Market value 252Market segmentation 253Market share 254Five forces analysis 255Market forecasts 266Macroeconomic indicators 267COMPANY PROFILES 269AstraZeneca PLC 269GlaxoSmithKline Plc 273Merck & Co., Inc. 278APPENDIX 282Data Research Methodology 282About Datamonitor 283Disclaimer 283

LIST OF TABLES

Table 1: Global pharmaceuticals market value: $ million, 2006–10 21

Table 2: Global pharmaceuticals market segmentation: % share, by value, 2010 22

Table 3: Global pharmaceuticals market share: % share, by value, 2010 23

Table 4: Global pharmaceuticals market value forecast: $ million, 2010–15 36

Table 5: Asia-Pacific pharmaceuticals market value: $ million, 2006–10 38

Table 6: Asia-Pacific pharmaceuticals market segmentation: % share, by value, 2010 39

Table 7: Asia-Pacific pharmaceuticals market share: % share, by value, 2010 40

Table 8: Asia-Pacific pharmaceuticals market value forecast: $ million, 2010–15 52

Table 9: Europe pharmaceuticals market value: $ million, 2006–10 54

Table 10: Europe pharmaceuticals market segmentation: % share, by value, 2010 55

Table 11: Europe pharmaceuticals market share: % share, by value, 2010 56

Table 12: Europe pharmaceuticals market value forecast: $ million, 2010–15 69

Table 13: Belgium pharmaceuticals market value: $ million, 2006–10 71

Table 14: Belgium pharmaceuticals market segmentation: % share, by value, 2010 72

Table 15: Belgium pharmaceuticals market share: % share, by value, 2010 73

Table 16: Belgium pharmaceuticals market value forecast: $ million, 2010–15 85

Table 17: Belgium size of population (million), 2006–10 86

Table 18: Belgium gdp (constant 2000 prices, $ billion), 2006–10 86

Table 19: Belgium gdp (current prices, $ billion), 2006–10 86

Table 20: Belgium inflation, 2006–10 87

Table 21: Belgium consumer price index (absolute), 2006–10 87

Table 22: Belgium exchange rate, 2006–10 87

Table 23: Canada pharmaceuticals market value: $ million, 2006–10 89

Table 24: Canada pharmaceuticals market segmentation: % share, by value, 2010 90

Table 25: Canada pharmaceuticals market share: % share, by value, 2010 91

Table 26: Canada pharmaceuticals market value forecast: $ million, 2010–15 103

Table 27: Canada size of population (million), 2006–10 104

Table 28: Canada gdp (constant 2000 prices, $ billion), 2006–10 104

Table 29: Canada gdp (current prices, $ billion), 2006–10 104

Table 30: Canada inflation, 2006–10 105

Table 31: Canada consumer price index (absolute), 2006–10 105

Table 32: Canada exchange rate, 2006–10 105

Table 33: China pharmaceuticals market value: $ million, 2006–10 107

Table 34: China pharmaceuticals market segmentation: % share, by value, 2010 108

Table 35: China pharmaceuticals market share: % share, by value, 2010 109

Table 36: China pharmaceuticals market value forecast: $ million, 2010–15 121

Table 37: China size of population (million), 2006–10 122

Table 38: China gdp (constant 2000 prices, $ billion), 2006–10 122

Table 39: China gdp (current prices, $ billion), 2006–10 122

Table 40: China inflation, 2006–10 123

Table 41: China consumer price index (absolute), 2006–10 123

Table 42: China exchange rate, 2006–10 123

Table 43: France pharmaceuticals market value: $ million, 2006–10 125

Table 44: France pharmaceuticals market segmentation: % share, by value, 2010 126

Table 45: France pharmaceuticals market share: % share, by value, 2010 127

Table 46: France pharmaceuticals market value forecast: $ million, 2010–15 139

Table 47: France size of population (million), 2006–10 140

Table 48: France gdp (constant 2000 prices, $ billion), 2006–10 140

Table 49: France gdp (current prices, $ billion), 2006–10 140

Table 50: France inflation, 2006–10 141

Table 51: France consumer price index (absolute), 2006–10 141

Table 52: France exchange rate, 2006–10 141

Table 53: Germany pharmaceuticals market value: $ million, 2006–10 143

Table 54: Germany pharmaceuticals market segmentation: % share, by value, 2010 144

Table 55: Germany pharmaceuticals market share: % share, by value, 2010 145

Table 56: Germany pharmaceuticals market value forecast: $ million, 2010–15 157

Table 57: Germany size of population (million), 2006–10 158

Table 58: Germany gdp (constant 2000 prices, $ billion), 2006–10 158

Table 59: Germany gdp (current prices, $ billion), 2006–10 158

Table 60: Germany inflation, 2006–10 159

Table 61: Germany consumer price index (absolute), 2006–10 159

Table 62: Germany exchange rate, 2006–10 159

Table 63: Italy pharmaceuticals market value: $ million, 2006–10 161

Table 64: Italy pharmaceuticals market segmentation: % share, by value, 2010 162

Table 65: Italy pharmaceuticals market share: % share, by value, 2010 163

Table 66: Italy pharmaceuticals market value forecast: $ million, 2010–15 175

Table 67: Italy size of population (million), 2006–10 176

Table 68: Italy gdp (constant 2000 prices, $ billion), 2006–10 176

Table 69: Italy gdp (current prices, $ billion), 2006–10 176

Table 70: Italy inflation, 2006–10 177

Table 71: Italy consumer price index (absolute), 2006–10 177

Table 72: Italy exchange rate, 2006–10 177

Table 73: Japan pharmaceuticals market value: $ million, 2006–10 179

Table 74: Japan pharmaceuticals market segmentation: % share, by value, 2010 180

Table 75: Japan pharmaceuticals market share: % share, by value, 2010 181

Table 76: Japan pharmaceuticals market value forecast: $ million, 2010–15 193

Table 77: Japan size of population (million), 2006–10 194

Table 78: Japan gdp (constant 2000 prices, $ billion), 2006–10 194

Table 79: Japan gdp (current prices, $ billion), 2006–10 194

Table 80: Japan inflation, 2006–10 195

Table 81: Japan consumer price index (absolute), 2006–10 195

Table 82: Japan exchange rate, 2006–10 195

Table 83: Netherlands pharmaceuticals market value: $ million, 2006–10 197

Table 84: Netherlands pharmaceuticals market segmentation: % share, by value, 2010 198

Table 85: Netherlands pharmaceuticals market share: % share, by value, 2010 199

Table 86: Netherlands pharmaceuticals market value forecast: $ million, 2010–15 212

Table 87: Netherlands size of population (million), 2006–10 213

Table 88: Netherlands gdp (constant 2000 prices, $ billion), 2006–10 213

Table 89: Netherlands gdp (current prices, $ billion), 2006–10 213

Table 90: Netherlands inflation, 2006–10 214

Table 91: Netherlands consumer price index (absolute), 2006–10 214

Table 92: Netherlands exchange rate, 2006–10 214

Table 93: Spain pharmaceuticals market value: $ million, 2006–10 216

Table 94: Spain pharmaceuticals market segmentation: % share, by value, 2010 217

Table 95: Spain pharmaceuticals market share: % share, by value, 2010 218

Table 96: Spain pharmaceuticals market value forecast: $ million, 2010–15 230

Table 97: Spain size of population (million), 2006–10 231

Table 98: Spain gdp (constant 2000 prices, $ billion), 2006–10 231

Table 99: Spain gdp (current prices, $ billion), 2006–10 231

Table 100: Spain inflation, 2006–10 232

Table 101: Spain consumer price index (absolute), 2006–10 232

Table 102: Spain exchange rate, 2006–10 232

Table 103: United Kingdom pharmaceuticals market value: $ million, 2006–10 234

Table 104: United Kingdom pharmaceuticals market segmentation: % share, by value, 2010 235

Table 105: United Kingdom pharmaceuticals market share: % share, by value, 2010 236

Table 106: United Kingdom pharmaceuticals market value forecast: $ million, 2010–15 248

Table 107: United Kingdom size of population (million), 2006–10 249

Table 108: United Kingdom gdp (constant 2000 prices, $ billion), 2006–10 249

Table 109: United Kingdom gdp (current prices, $ billion), 2006–10 249

Table 110: United Kingdom inflation, 2006–10 250

Table 111: United Kingdom consumer price index (absolute), 2006–10 250

Table 112: United Kingdom exchange rate, 2006–10 250

Table 113: United States pharmaceuticals market value: $ million, 2006–10 252

Table 114: United States pharmaceuticals market segmentation: % share, by value, 2010 253

Table 115: United States pharmaceuticals market share: % share, by value, 2010 254

Table 116: United States pharmaceuticals market value forecast: $ million, 2010–15 266

Table 117: United States size of population (million), 2006–10 267

Table 118: United States gdp (constant 2000 prices, $ billion), 2006–10 267

Table 119: United States gdp (current prices, $ billion), 2006–10 267

Table 120: United States inflation, 2006–10 268

Table 121: United States consumer price index (absolute), 2006–10 268

Table 122: United States exchange rate, 2006–10 268

Table 123: AstraZeneca PLC: key facts 269

Table 124: AstraZeneca PLC: key financials ($) 271

Table 125: AstraZeneca PLC: key financial ratios 271

Table 126: GlaxoSmithKline Plc: key facts 273

Table 127: GlaxoSmithKline Plc: key financials ($) 275

Table 128: GlaxoSmithKline Plc: key financials (£) 276

Table 129: GlaxoSmithKline Plc: key financial ratios 276

Table 130: Merck & Co., Inc.: key facts 278

Table 131: Merck & Co., Inc.: key financials ($) 279

Table 132: Merck & Co., Inc.: key financial ratios 280

LIST OF FIGURESFigure 1: Global pharmaceuticals market value: $ million, 2006–10 21Figure 2: Global pharmaceuticals market segmentation: % share, by value, 2010 22Figure 3: Global pharmaceuticals market share: % share, by value, 2010 23Figure 4: Forces driving competition in the global pharmaceuticals market, 2010 24Figure 5: Drivers of buyer power in the global pharmaceuticals market, 2010 26Figure 6: Drivers of supplier power in the global pharmaceuticals market, 2010 28Figure 7: Factors influencing the likelihood of new entrants in the global pharmaceuticals market, 2010 30Figure 8: Factors influencing the threat of substitutes in the global pharmaceuticals market, 2010 32Figure 9: Drivers of degree of rivalry in the global pharmaceuticals market, 2010 34Figure 10: Global pharmaceuticals market value forecast: $ million, 2010–15 36Figure 11: Asia-Pacific pharmaceuticals market value: $ million, 2006–10 38Figure 12: Asia-Pacific pharmaceuticals market segmentation: % share, by value, 2010 39Figure 13: Asia-Pacific pharmaceuticals market share: % share, by value, 2010 40Figure 14: Forces driving competition in the pharmaceuticals market in Asia-Pacific, 2010 41Figure 15: Drivers of buyer power in the pharmaceuticals market in Asia-Pacific, 2010 43Figure 16: Drivers of supplier power in the pharmaceuticals market in Asia-Pacific, 2010 45Figure 17: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Asia-Pacific, 2010 47Figure 18: Factors influencing the threat of substitutes in the pharmaceuticals market in Asia-Pacific, 2010 49Figure 19: Drivers of degree of rivalry in the pharmaceuticals market in Asia-Pacific, 2010 50Figure 20: Asia-Pacific pharmaceuticals market value forecast: $ million, 2010–15 52Figure 21: Europe pharmaceuticals market value: $ million, 2006–10 54Figure 22: Europe pharmaceuticals market segmentation: % share, by value, 2010 55Figure 23: Europe pharmaceuticals market share: % share, by value, 2010 56Figure 24: Forces driving competition in the pharmaceuticals market in Europe, 2010 57Figure 25: Drivers of buyer power in the pharmaceuticals market in Europe, 2010 59Figure 26: Drivers of supplier power in the pharmaceuticals market in Europe, 2010 61Figure 27: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Europe, 2010 63Figure 28: Factors influencing the threat of substitutes in the pharmaceuticals market in Europe, 2010 65Figure 29: Drivers of degree of rivalry in the pharmaceuticals market in Europe, 2010 67Figure 30: Europe pharmaceuticals market value forecast: $ million, 2010–15 69Figure 31: Belgium pharmaceuticals market value: $ million, 2006–10 71Figure 32: Belgium pharmaceuticals market segmentation: % share, by value, 2010 72Figure 33: Belgium pharmaceuticals market share: % share, by value, 2010 73Figure 34: Forces driving competition in the pharmaceuticals market in Belgium, 2010 74Figure 35: Drivers of buyer power in the pharmaceuticals market in Belgium, 2010 75Figure 36: Drivers of supplier power in the pharmaceuticals market in Belgium, 2010 77Figure 37: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Belgium, 2010 79Figure 38: Factors influencing the threat of substitutes in the pharmaceuticals market in Belgium, 2010 81Figure 39: Drivers of degree of rivalry in the pharmaceuticals market in Belgium, 2010 83Figure 40: Belgium pharmaceuticals market value forecast: $ million, 2010–15 85Figure 41: Canada pharmaceuticals market value: $ million, 2006–10 89Figure 42: Canada pharmaceuticals market segmentation: % share, by value, 2010 90Figure 43: Canada pharmaceuticals market share: % share, by value, 2010 91Figure 44: Forces driving competition in the pharmaceuticals market in Canada, 2010 92Figure 45: Drivers of buyer power in the pharmaceuticals market in Canada, 2010 93Figure 46: Drivers of supplier power in the pharmaceuticals market in Canada, 2010 95Figure 47: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2010 97Figure 48: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2010 99Figure 49: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2010 101Figure 50: Canada pharmaceuticals market value forecast: $ million, 2010–15 103Figure 51: China pharmaceuticals market value: $ million, 2006–10 107Figure 52: China pharmaceuticals market segmentation: % share, by value, 2010 108Figure 53: China pharmaceuticals market share: % share, by value, 2010 109Figure 54: Forces driving competition in the pharmaceuticals market in China, 2010 110Figure 55: Drivers of buyer power in the pharmaceuticals market in China, 2010 111Figure 56: Drivers of supplier power in the pharmaceuticals market in China, 2010 113Figure 57: Factors influencing the likelihood of new entrants in the pharmaceuticals market in China, 2010 115Figure 58: Factors influencing the threat of substitutes in the pharmaceuticals market in China, 2010 117Figure 59: Drivers of degree of rivalry in the pharmaceuticals market in China, 2010 119Figure 60: China pharmaceuticals market value forecast: $ million, 2010–15 121Figure 61: France pharmaceuticals market value: $ million, 2006–10 125Figure 62: France pharmaceuticals market segmentation: % share, by value, 2010 126Figure 63: France pharmaceuticals market share: % share, by value, 2010 127Figure 64: Forces driving competition in the pharmaceuticals market in France, 2010 128Figure 65: Drivers of buyer power in the pharmaceuticals market in France, 2010 129Figure 66: Drivers of supplier power in the pharmaceuticals market in France, 2010 131Figure 67: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2010 133Figure 68: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2010 135Figure 69: Drivers of degree of rivalry in the pharmaceuticals market in France, 2010 137Figure 70: France pharmaceuticals market value forecast: $ million, 2010–15 139Figure 71: Germany pharmaceuticals market value: $ million, 2006–10 143Figure 72: Germany pharmaceuticals market segmentation: % share, by value, 2010 144Figure 73: Germany pharmaceuticals market share: % share, by value, 2010 145Figure 74: Forces driving competition in the pharmaceuticals market in Germany, 2010 146Figure 75: Drivers of buyer power in the pharmaceuticals market in Germany, 2010 147Figure 76: Drivers of supplier power in the pharmaceuticals market in Germany, 2010 149Figure 77: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2010 151Figure 78: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2010 153Figure 79: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2010 155Figure 80: Germany pharmaceuticals market value forecast: $ million, 2010–15 157Figure 81: Italy pharmaceuticals market value: $ million, 2006–10 161Figure 82: Italy pharmaceuticals market segmentation: % share, by value, 2010 162Figure 83: Italy pharmaceuticals market share: % share, by value, 2010 163Figure 84: Forces driving competition in the pharmaceuticals market in Italy, 2010 164Figure 85: Drivers of buyer power in the pharmaceuticals market in Italy, 2010 165Figure 86: Drivers of supplier power in the pharmaceuticals market in Italy, 2010 167Figure 87: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Italy, 2010 169Figure 88: Factors influencing the threat of substitutes in the pharmaceuticals market in Italy, 2010 171Figure 89: Drivers of degree of rivalry in the pharmaceuticals market in Italy, 2010 173Figure 90: Italy pharmaceuticals market value forecast: $ million, 2010–15 175Figure 91: Japan pharmaceuticals market value: $ million, 2006–10 179Figure 92: Japan pharmaceuticals market segmentation: % share, by value, 2010 180Figure 93: Japan pharmaceuticals market share: % share, by value, 2010 181Figure 94: Forces driving competition in the pharmaceuticals market in Japan, 2010 182Figure 95: Drivers of buyer power in the pharmaceuticals market in Japan, 2010 183Figure 96: Drivers of supplier power in the pharmaceuticals market in Japan, 2010 185Figure 97: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2010 187Figure 98: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2010 189Figure 99: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2010 191Figure 100: Japan pharmaceuticals market value forecast: $ million, 2010–15 193Figure 101: Netherlands pharmaceuticals market value: $ million, 2006–10 197Figure 102: Netherlands pharmaceuticals market segmentation: % share, by value, 2010 198Figure 103: Netherlands pharmaceuticals market share: % share, by value, 2010 199Figure 104: Forces driving competition in the pharmaceuticals market in the Netherlands, 2010 200Figure 105: Drivers of buyer power in the pharmaceuticals market in the Netherlands, 2010 201Figure 106: Drivers of supplier power in the pharmaceuticals market in the Netherlands, 2010 203Figure 107: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the Netherlands, 2010 205Figure 108: Factors influencing the threat of substitutes in the pharmaceuticals market in the Netherlands, 2010 208Figure 109: Drivers of degree of rivalry in the pharmaceuticals market in the Netherlands, 2010 210Figure 110: Netherlands pharmaceuticals market value forecast: $ million, 2010–15 212Figure 111: Spain pharmaceuticals market value: $ million, 2006–10 216Figure 112: Spain pharmaceuticals market segmentation: % share, by value, 2010 217Figure 113: Spain pharmaceuticals market share: % share, by value, 2010 218Figure 114: Forces driving competition in the pharmaceuticals market in Spain, 2010 219Figure 115: Drivers of buyer power in the pharmaceuticals market in Spain, 2010 220Figure 116: Drivers of supplier power in the pharmaceuticals market in Spain, 2010 222Figure 117: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Spain, 2010 224Figure 118: Factors influencing the threat of substitutes in the pharmaceuticals market in Spain, 2010 226Figure 119: Drivers of degree of rivalry in the pharmaceuticals market in Spain, 2010 228Figure 120: Spain pharmaceuticals market value forecast: $ million, 2010–15 230Figure 121: United Kingdom pharmaceuticals market value: $ million, 2006–10 234Figure 122: United Kingdom pharmaceuticals market segmentation: % share, by value, 2010 235Figure 123: United Kingdom pharmaceuticals market share: % share, by value, 2010 236Figure 124: Forces driving competition in the pharmaceuticals market in the United Kingdom, 2010 237Figure 125: Drivers of buyer power in the pharmaceuticals market in the United Kingdom, 2010 238Figure 126: Drivers of supplier power in the pharmaceuticals market in the United Kingdom, 2010 240Figure 127: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United Kingdom, 2010 242Figure 128: Factors influencing the threat of substitutes in the pharmaceuticals market in the United Kingdom, 2010 244Figure 129: Drivers of degree of rivalry in the pharmaceuticals market in the United Kingdom, 2010 246Figure 130: United Kingdom pharmaceuticals market value forecast: $ million, 2010–15 248Figure 131: United States pharmaceuticals market value: $ million, 2006–10 252Figure 132: United States pharmaceuticals market segmentation: % share, by value, 2010 253Figure 133: United States pharmaceuticals market share: % share, by value, 2010 254Figure 134: Forces driving competition in the pharmaceuticals market in the United States, 2010 255Figure 135: Drivers of buyer power in the pharmaceuticals market in the United States, 2010 256Figure 136: Drivers of supplier power in the pharmaceuticals market in the United States, 2010 258Figure 137: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2010 260Figure 138: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2010 262Figure 139: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2010 264Figure 140: United States pharmaceuticals market value forecast: $ million, 2010–15 266Figure 141: AstraZeneca PLC: revenues & profitability 272Figure 142: AstraZeneca PLC: assets & liabilities 272Figure 143: GlaxoSmithKline Plc: revenues & profitability 277Figure 144: GlaxoSmithKline Plc: assets & liabilities 277Figure 145: Merck & Co., Inc.: revenues & profitability 280Figure 146: Merck & Co., Inc.: assets & liabilities 281

To order this report:Pharmaceutical Industry: Pharmaceuticals: Global Industry Guide

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021
2. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects?
3. Reportlinker Adds Process Analytical Technologies for Pharmaceuticals: Global Markets
4. Reportlinker Adds OTC Pharmaceuticals: Global Industry Almanac
5. VIDEO from thenewsmarket.com and Roche Pharmaceuticals: MabThera Approved in Europe for First Line Maintenance Treatment of Follicular Lymphoma, a Common Type of Blood Cancer
6. Reportlinker Adds Gastrointestinal Pharmaceuticals: Technologies and Markets
7. GlobalSpec Medical Equipment Design Online Trade Show and Event Draws More Than 1,100 Attendees
8. Philips and the World Association of Sleep Medicine Join Together to Raise Global Awareness of the Importance of Sleep
9. Global Call for Mercury-free Vaccines Issued
10. Marken Validates Top Position in Global Clinical Sample Shipments
11. Ricky Gervais Launches Global Campaign to end Cosmetic Tests on Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , February 11, 2016 --> ... of a new research report, titled "Sports Medicine Devices Market ... 2013 - 2019". According to the report, the global sports ... CAGR from 2013 to 2019, growing from a value of ... --> --> The global sports ...
(Date:2/11/2016)... , February 11, 2016 Jeffrey ... Worldwide Clinical Trials, will present at this year,s Summit for ... Hyatt Regency in Miami, FL. Zucker ... to optimize study execution, supporting SCOPE,s "Improving Site Study Activation ... place on Thursday, Feb. 25 at 11:05 a.m. ...
(Date:2/11/2016)... F ast access ... at the point of need ... medical information products and services, has launched a ClinicalKey mobile ... a mobile device. Elsevier designed the mobile app to allow users to ... available in Android and iOS formats for mobile ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... ... Florida Hospital presents Heart Health Awareness night on Sunday February 14th, as ... The puck drops at 6:00pm, but fans will have the opportunity to experience the ... The MEGA Heart will be located on Ford Thunder Alley and provide fans with ...
(Date:2/11/2016)... ... February 11, 2016 , ... The president released a FY 2017 ... but would shift more of the cost burden to military beneficiaries. , MOAA’s ... in the defense budget as including limited quantifiable benefit fixes mixed with numerous beneficiary ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... discuss how to improve care by making data on heart procedures public and ... Summit on Transparency and Public Reporting of Pediatric and Congenital Heart Disease Outcomes ...
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, ... Benefit Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. ... with Intel on value-based health benefits program Connected Care, will discuss the challenges ...
(Date:2/11/2016)... ... 11, 2016 , ... "What holds you back from ... a question as a challenge for his readers to examine the full scale ... (published by Partridge Singapore), Clarke explores the subject with more depth, revealing time-honored ...
Breaking Medicine News(10 mins):